

| | | | |
|---|--------|--------------------------|----------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10582704 |
| | | Filing Date | 2004-12-14 |
| | | First Named Inventor | Maria Isabel Crespo Crespo |
| | | Group Art Unit | 1624 |
| | | Examiner Name | Deepak Rao |
| Sheet | 1 of 3 | Attorney Docket Number | LABO-003/02US 311815-2022 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | US- 4725600 | 1988-02-16 | TAKAYA, et al. | |
| | | US- 5138058 | 1992-08-11 | GEISEN, et al. | |
| | | US- 6156755 | 2000-12-05 | GEISEN, Karl | |
| | | US- 6518424 | 2003-02-11 | JOHN, et al. | |
| | | US- 6562811 | 2003-05-13 | MURATA, et al. | |
| | | US- 6586441 | 2003-07-01 | BORRONI, et al. | |
| | | US- 6716851 | 2004-04-06 | CAI, et al. | |
| | | US- 6844347 | 2005-01-18 | SCHINDLER, et al. | |
| | | US- 20010027196 | 2001-10-04 | BORRONI, EDILIO MAURIZIO, et al. | |
| | | US- 20030078271 | 2003-04-24 | BLACKBURN, et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|--|--------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ Number* Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | EP0407899 | 1991-01-16 | Hoescht, AG | T ⁶ |
| | | EP0459830 | 1991-12-04 | The Wellcome Foundation Ltd. | |
| | | EP0767170 | 1997-04-09 | Taiho Pharmaceutical Co. | |
| | | JP06192252 | 1994-07-12 | Nissan Chemical Ind. Ltd. | |
| | | JP11158073 | 1999-06-15 | Takeda Chem. Ind. Ltd. | |
| | | JP2001089452 | 2001-04-03 | Sankyo Co. | |
| | | JP2001199982 | 2004-07-24 | Dainippon Pharmaceutical Co. | |
| | | JP2003206230 | 2003-07-22 | Yamanouchi Pharma. Co. Ltd. | |
| | | JP54115384 | 1979-09-07 | Hokko Chem. Ind. Co. | |
| | | JP54117029 | 1979-09-11 | Hokko Chem. Ind. Co. | |
| | | JP54147921 | 1979-11-19 | Hokko Chem. Ind. Co. | |
| | | WO01047921 | 2001-07-05 | Pharmacopeia Inc. | |
| | | WO02022602 | 2002-03-21 | Vertex Pharmaceuticals Inc. | |
| | | WO03035639 | 2003-05-01 | Eisai Co. Ltd. | |
| | | WO03049739 | 2003-06-19 | Vertex Pharmaceuticals Inc. | |
| | | WO03068757 | 2003-08-21 | F. Hoffman-La Roche AG | |
| | | WO03077656 | 2003-09-25 | Ciba Specialty Chemicals Holding Inc. | |
| | | WO04014307 | 2004-02-19 | Synaptic Pharmaceutical Corp. | |
| | | WO2004048365 | 2004-06-10 | Chiron Corporation | |
| | | WO2005033084 | 2005-04-15 | Universiteit Leiden | |
| | | WO2005033085 | 2005-04-15 | Universiteit Leiden | |
| | | WO2006110884 | 2006-10-19 | Neurocrine Biosciences, Inc., Almirall | |
| | | WO2007084914 | 2007-07-26 | Neurocrine Biosciences, Inc., Almirall | |
| | | WO2008070661 | 2008-06-12 | Neurocrine Biosciences, Inc., Almirall | |
| | | WO9824782 | 1998-06-11 | Amgen Inc. | |

| | | | |
|---|--------|--------------------------|----------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 10582704 |
| | | Filing Date | 2004-12-14 |
| | | First Named Inventor | Maria Isabel Crespo Crespo |
| | | Group Art Unit | 1624 |
| | | Examiner Name | Deepak Rao |
| Sheet | 2 of 3 | Attorney Docket Number | LABO-003/02US 311815-2022 |

| OTHER – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | | BARALDI, P. G., et al., Pyrazolo[4,3,e]-1,2,4-triazolo-[1,5-c]pyrimidine Derivatives as highly potent and Selective A3 Adenosine Receptor Antagonists: Influence of the Chain at the N8 Pyrazolem Nitrogen. Journal of Medicinal Chemistry, 2000, 4768-4780, 43. | |
| | | BARALDI, P. G., et al., Pyrazolo[4,3,e]-1,2,4-triazolo-[1,5-c]pyrimidine Derivatives: potent and Selective A2a Adenosine Antagonist. Journal of Medicinal Chemistry, 1996, 1164-1171, 39. | |
| | | BREDERICK, Helmut, et al. Trisacetylaminomethane: Synthesen und Umsetzungen, Chem Ber, 1963, 1505-1514, 96. | |
| | | BROWN, D. J. et al., Heterocyclic Amplifiers of Phenomycin. I. Some Pyrimidinylpurines, Pyrimidinylpteridines and Phenylpyrimidines. Journal of Chemistry, 1984, 155-163, 37. | |
| | | CHANG, Lisa C. W., et al., 2, 4, 6-Trisubstituted Pyrimidines as a New Class of Selective Adenosine A1 receptor Antagonists, J. Med. Chem., 2004, 6529-6540, 47. | |
| | | CHAPMAN, N. B., et al., Nucleophilic Displacement Reaction in Aromatic Systems Part III. J Chem Soc., 1954, 1190-1192. | |
| | | CHENG, et al., Biochem. Pharm. 22:3099-3108, 1973. | |
| | | CONDRET, C. Synthetic Communications 1996, Vol. 26, No. 19, p. 3543-3547. | |
| | | DALL'IGNA, et al., "Caffeine and adenosine A2a receptor antagonists prevent β -amyloid (25-35)-induced cognitive deficits in mice" Experimental Neurology, 2007; Vol. 203, p. 241-245. | |
| | | Database Crossfire Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften, Frankfurt AM Main, DE; Database-Accession No. 2983888 (BRN) XP002495819 Abstract & Justus Liebig's Annalen Der Chemie, Vol. 704, 1967, p. 144-149, DE. | |
| | | DEVALK, J. et al., On the Mechanism of the Amination of 2-Bromo-2,6-diphenyl-pyrimidine with Potassium Amide in Liquid Ammonia. Recueil, 1973, 155-163, 92. | |
| | | EL-SHENAWY, A. I. et al., Synthesis of Some Heterocyclic Compounds Bearing a Maleimido Moiety, Egyptian Journal of Chemistry, 2002, 895-904, 45. | |
| | | European Application EP06750082.7 Office Action mailed 04.28.09. | |
| | | European Application EP06750082.7 Office Action mailed 09.18.08 | |
| | | European Application EP04814183.2 Office Action mailed 03.09.10. | |
| | | European Application EP04814183.2 Office Action mailed 08.04.09. | |
| | | European Application EP04814183.2 Office Action mailed 09.03.10. | |
| | | European Application EP07718002.4 Office Action mailed 04.01.09 | |
| | | European Application EP07718002.4 Office Action mailed 10.14.10 | |
| | | European Application 08732707.8 Office Action mailed 02.16.10. | |
| | | FAROUK H. et al., "Reaction of alpha,beta-unsaturated ketones with guanidine. Substituent effects on the protonation constants of 2-amino-4,6-diarylpyrimidines." J. Heterocyclic Chem., 1982 1087-1092, 19. | |
| | | FREDHOLM, B. B., et al., International Union of Pharmacology.XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacological Reviews 2001, p. 527-552, 53. | |
| | | GOTOR, Vincente, et al., Synthesis and Rearrangement of 5-Isocyanatopyrazolines, Tetrahedron, 1989, 1783-1792, 45. | |
| | | HENZE, et al., Researches on Pyrimidines: Certain Derivatives of 2-Propylpyrimidine, J. Amer. Chem. Soc. 1957, 2230-2232, 79. | |
| | | HESS, S., et al., &-Deazaadenines Bearing Polar Substituents; Structure-Activity Relationships of New A1 and A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 4636-4646, 43. | |
| | | Israel Patent Application 176,005 Office Action dated on or around 01.16.09. | |

| | | | | |
|---|------------|--------------------------|----------------------------|--|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | |
| | | Application Number | 10582704 | |
| | | Filing Date | 2004-12-14 | |
| | | First Named Inventor | Maria Isabel Crespo Crespo | |
| | | Group Art Unit | 1624 | |
| Examiner Name | Deepak Rao | | | |
| Sheet | 3 of 3 | Attorney Docket Number | LABO-003/02US 311815-2022 | |

| | |
|--|---|
| | KABBE, "Substituierte 4-Hydroxy- und 4-Amino-Pyrimidine" JUSTUS LIEBIGS ANNALEN DER CHEMIE, Vol. 704, 1967, p. 144-149, XP008090403. |
| | KIM, et al. "Modeling the Adenosine Receptors: Comparison of the Binding Domains of A2A Agonists and Antagonists" Journal of Medicinal Chemistry, Nov. 6, 2003, LNKD-PUBMED: 14584936, ISSN: 0022-2623, Vol. 46, No. 23, Nov. 6, 2003, p. 4847-4859. |
| | LARDENOIS Patrick et al, Tautomerie des composés heterocycliques. Bulletin de la Société de Chimie de France, 1971, 1858-1868. |
| | MAMAEV, V. P., et al., New Method for the Synthesis of 2-Aminopyrimidines, Chem. Heterocycl. Compd. 1975, 1322-1324, 11. |
| | Mexico Patent Application PA/z/2006/006776 Office Action dated on or around 07.28.09. |
| | MULLER, C. E. "A2A Adenosine Receptor Antagonists - Future Drugs for Parkinson's Disease?" Drugs of the Future, Prous Science, ES LNkd - DOI: 10.1358/DOF.2000.025.10.858696, Vol. 25, No. 10, 1 January 2000 (2000-01-01), p. 1043-1052, XP008035142 ISSN: 037 |
| | PCT Application PCT/US2004/041970 International Search Report, IPRP and WOIP mailed 04.20.05 |
| | PCT/US2007/086380 IPRP and Written Opinion mailed 06.10.09. |
| | PCT/US2007/086380 ISR mailed 04.22.08. |
| | PCT/US2008/057911 IPRP and Written Opinion 10.01.09. |
| | PCT/US2008/057911 ISR mailed 01.16.09. |
| | PRIEGO, E. M., et al., Pyrido[2,1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2002, 3337-3344, 45. |
| | SARGES, R., et al., 4-Amino[1,2,4]triazolo[4,3-a]quinazolines. A Novel Class of Potent Adenosine Receptor Antagonists and Potential Rapid-Onset Antidepressants. Journal of Medicinal Chemistry, 1990, 2240-2254, 33. |
| | TYRELL, E. et al., Synthesis 2003 Vol 4, p. 469-483 |
| | VAN GALEN, P. J., et al., Imidazo[4,5-c]quinolin-4-amines: Novel Xanthine Adenosine Agonists. Journal of Medicinal Chemistry, 1991, p. 1202-1206, 34. |
| | WHEELER, Henry L., Researches on Poyrimidines: On Some Salts of Cytosin, Isocytosin, 6-Aminopyrimidin and 6-Oxypyrimidin, J Biol Chem 1907, 285-297, 3. |
| | ZHANG, J. Org. Chem., 2005, 70, 5164. |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Unique citation designation number (optional). *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.